Newsfeeds - Spark Newswire

1 minute read

Earnings

Atara Biotherapeutics: Q2 Earnings Insights

Today, 1:00 PM

Atara Biotherapeutics (NASDAQ:ATRA) reported its Q2 earnings results on Monday, August 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Atara Biotherapeutics reported an EPS of $-0.31.

ATRA

6 minute read

Stocks That Hit 52-Week Lows On Monday

By Benzinga Insights

Today, 1:00 PM

On Monday, 92 companies set new 52-week lows.

ABVC

7 minute read

Stocks That Hit 52-Week Lows On Monday

By Benzinga Insights

Today, 1:00 PM

On Monday, 100 companies reached new 52-week lows.

4 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 1:00 PM

During Friday's session, 61 companies made new 52-week lows.

APDN

1 minute read

Citigroup Downgrades Atara Biotherapeutics to Sell, Announces $3 Price Target

By Benzinga Newsdesk

Today, 1:00 PM

Citigroup analyst Yigal Nochomovitz downgrades Atara Biotherapeutics (NASDAQ:ATRA) from Neutral to Sell and announces $3 price target.

ATRA

5 minute read

Twitter Shares Surge Around 8%, Here’s 66 Biggest Movers From Yesterday

By Lisa Levin

Today, 1:00 PM

Gainers Qurate Retail, Inc. (NASDAQ: QRTEB) shares climbed 71.1% to close at $5.20. Qurate Retail will host a conference call to discuss Q2 results on Friday, August 5th.

ABEV

2 minute read

12 Health Care Stocks Moving In Wednesday’s Intraday Session

By Benzinga Insights

Today, 1:00 PM

AGTC

3 minute read

Dow Drops 100 Points; US Budget Deficit Narrows Sharply In June

By Lisa Levin

Today, 1:00 PM

U.S. stocks traded mixed toward the end of trading, with the S&P 500 and Nasdaq Composite moving higher on Wednesday. The annual inflation rate in the US increased to 9.1% in June, the highest level since November 1981.

AGTC

1 minute read

Mizuho On Atara Biotherapeutics – Distinguish Between Small Numbers And Science Failure

By Vandana Singh

Today, 1:00 PM

Atara Biotherapeutics Inc (NASDAQ:ATRA) issued its anticipated interim analysis communication for its ATA188 Phase 2 progressive multiple sclerosis trial. Shares slumped…

ATRA